Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 46.2 0.48% 0.22
APLS closed up 0.48 percent on Wednesday, February 24, 2021, on 67 percent of normal volume.
Earnings due: Feb 25
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat
Historical APLS trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Bullish Engulfing Bullish 0.48%
Crossed Above 20 DMA Bullish 0.48%
Pocket Pivot Bullish Swing Setup 0.48%
Bollinger Band Squeeze Range Contraction 0.48%
Outside Day Range Expansion 0.48%
20 DMA Resistance Bearish 1.99%
Bollinger Band Squeeze Range Contraction 1.99%
Older End-of-Day Signals for APLS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 17 hours ago
Rose Above 10 DMA about 17 hours ago
20 DMA Support about 18 hours ago
Down 2 % about 19 hours ago
Down 1% about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Apellis Pharmaceuticals, Inc. Description

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Eye Organ Systems Inflammatory Disease Inflammatory Diseases Macular Degeneration Related Macular Degeneration Pulmonary Disease Chronic Obstructive Pulmonary Disease Hemoglobin Autoimmune And Inflammatory Disease Autoimmune And Inflammatory Diseases Complement System C3 Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Treatment Of Chronic Obstructive Pulmonary Disease Acquired Hemolytic Anemia Intravitreal Administration Pnh Copd Intravitreal Injection

Is APLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 58.47
52 Week Low 16.85
Average Volume 642,824
200-Day Moving Average 37.65
50-Day Moving Average 50.22
20-Day Moving Average 45.93
10-Day Moving Average 46.04
Average True Range 2.47
ADX 23.88
+DI 13.52
-DI 24.09
Chandelier Exit (Long, 3 ATRs ) 43.05
Chandelier Exit (Short, 3 ATRs ) 49.31
Upper Bollinger Band 49.04
Lower Bollinger Band 42.82
Percent B (%b) 0.54
BandWidth 13.55
MACD Line -0.96
MACD Signal Line -1.09
MACD Histogram 0.1315
Fundamentals Value
Market Cap 3.49 Billion
Num Shares 75.6 Million
EPS -3.32
Price-to-Earnings (P/E) Ratio -13.91
Price-to-Sales 4846.49
Price-to-Book 33.50
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 49.11
Resistance 3 (R3) 49.04 48.01 48.63
Resistance 2 (R2) 48.01 47.27 48.04 48.46
Resistance 1 (R1) 47.10 46.81 46.59 47.17 48.30
Pivot Point 46.07 46.07 45.81 46.10 46.07
Support 1 (S1) 45.16 45.33 44.65 45.23 44.10
Support 2 (S2) 44.13 44.87 44.16 43.94
Support 3 (S3) 43.22 44.13 43.78
Support 4 (S4) 43.29